Gilead Sciences, Inc. $GILD Stock Sold by Calamos Advisors LLC

Calamos Advisors LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 320,159 shares of the biopharmaceutical company’s stock after selling 36,329 shares during the period. Calamos Advisors LLC’s holdings in Gilead Sciences were worth $47,720,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Alta Advisers Ltd raised its stake in Gilead Sciences by 80.2% during the 3rd quarter. Alta Advisers Ltd now owns 8,997 shares of the biopharmaceutical company’s stock worth $1,341,000 after acquiring an additional 4,005 shares during the period. Syverson Strege & Co lifted its stake in shares of Gilead Sciences by 6.9% during the 3rd quarter. Syverson Strege & Co now owns 3,570 shares of the biopharmaceutical company’s stock valued at $532,000 after buying an additional 229 shares in the last quarter. Principle Wealth Partners LLC raised its holdings in Gilead Sciences by 15.7% during the third quarter. Principle Wealth Partners LLC now owns 2,788 shares of the biopharmaceutical company’s stock valued at $416,000 after acquiring an additional 378 shares during the period. REAP Financial Group LLC raised its holdings in Gilead Sciences by 11.4% during the third quarter. REAP Financial Group LLC now owns 1,380 shares of the biopharmaceutical company’s stock valued at $206,000 after acquiring an additional 141 shares during the period. Finally, Telos Capital Management Inc. purchased a new position in shares of Gilead Sciences in the third quarter valued at about $215,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on GILD. Bank of America increased their target price on Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a research report on Tuesday, October 20th. Needham & Company LLC set a $175.00 price target on Gilead Sciences in a report on Friday, October 30th. Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Sanford C. Bernstein reiterated an “outperform” rating and set a $175.00 price objective on shares of Gilead Sciences in a research report on Monday. Finally, UBS Group lifted their price objective on shares of Gilead Sciences from $175.00 to $195.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Twenty-three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $170.15.

Insider Activity

In other news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total transaction of $468,660.00. Following the transaction, the insider owned 113,684 shares of the company’s stock, valued at approximately $17,759,714.48. This represents a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 9,810 shares of the company’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $175.17, for a total value of $1,718,417.70. Following the completion of the transaction, the chief executive officer directly owned 551,683 shares in the company, valued at $96,638,311.11. This trade represents a 1.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 239,310 shares of company stock valued at $38,945,617. 0.30% of the stock is currently owned by company insiders.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: New HIV-prevention data showed twice-yearly lenacapavir achieved nearly twice the one-year treatment persistence of daily oral F/TDF, a result that could support Gilead’s long-acting HIV-prevention strategy. Article: New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence
• Positive Sentiment: In the Phase 3 IDEAL study, Livdelzi (seladelpar) achieved ALP normalization in about 75% of participants with primary biliary cholangitis. The results may strengthen its case for broader second-line use, although the stock reportedly fell following the update. Article: Gilead’s Livdelzi Achieves 75% ALP Normalization
• Positive Sentiment: Recent third-quarter results beat analyst estimates for earnings and revenue, and Gilead raised full-year product-sales guidance. The company also maintained its quarterly dividend at $0.82 per share. Article: Did Earnings Beat Just Shift Gilead Sciences’ Investment Narrative?
• Neutral Sentiment: CEO Daniel O’Day sold more than 112,000 shares across November 4–5, but the transactions were conducted under a pre-arranged Rule 10b5-1 plan. He retained 551,683 shares, which may temper concerns about the sales. SEC Form 4 filing

Gilead Sciences Trading Down 0.4%

GILD stock traded down $0.68 during midday trading on Friday, reaching $166.89. 5,817,414 shares of the company traded hands, compared to its average volume of 6,406,722. Gilead Sciences, Inc. has a 52-week low of $116.88 and a 52-week high of $176.58. The company has a debt-to-equity ratio of 1.84, a quick ratio of 0.95 and a current ratio of 1.38. The business has a 50 day moving average of $153.04 and a 200-day moving average of $140.94. The firm has a market capitalization of $207.00 billion, a price-to-earnings ratio of -52.81 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The firm had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. During the same quarter in the previous year, the business earned $2.47 EPS. The company’s quarterly revenue was up 6.8% on a year-over-year basis. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post -1.07 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.0%. Gilead Sciences’s dividend payout ratio is currently -103.80%.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C.

Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.